RxDoctor Payments Data

Jorge Kourie, MD

Nephrology · Orlando, FLNPI 1659585552

Payments from drug & device makers

$39,077in general payments, 2019–2025

Across 326 payments — averaging $119.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$19K
  • Boehringer Ingelheim$8K
  • Gilead$4K
  • Veloxis Pharmaceuticals, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • AstraZeneca$560
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$3,1408%
  • Speaking & faculty fees$27,78071%
  • Travel & lodging$1,0073%
  • Food & beverage$6,78217%
  • Education$3681%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,077 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$289,351
Medicare patients
426
Services billed
3,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NulojixBelatacept27$67,560
FarxigaDapagliflozin Propanediol47$44,496
JardianceEmpagliflozin47$39,137
Cinacalcet Hcl68$27,804
Everolimus12$25,044
KerendiaFinerenone29$23,882
Valganciclovir Hcl55$19,881
LinzessLinaclotide11$17,888
LokelmaSodium Zirconium Cyclosilicate11$6,930
Tacrolimus36$2,075
Hydralazine Hcl86$1,904
Nifedipine ErNifedipine49$1,852
Bumetanide33$1,723
Leflunomide26$1,470
Prednisone226$1,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Nulojix$16$67,56027 claims
AstraZenecaFarxiga, Lokelma$560$51,42758 claims
Boehringer IngelheimJardiance$7,755$39,13747 claims
BayerKerendia$195$23,88229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →